NVS vs RIGL
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. RIGL: Rigel is a commercial-stage biotech with three FDA-approved, niche oncology/hematology drugs generating strong revenue growth and a clinical pipeline of novel kinase inhibitors for rare blood disorders and cancers.
Side-by-side fundamentals
| Metric | NVS | RIGL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.08 | $37.80 | |
| Market cap as of 2026-07-23 | $229.2B | $714M | |
| P/E as of 2026-07-23 | 22.11 | 1.96 | RIGL lower |
| PEG as of 2026-07-23 | 3.66 | 0.00 | RIGL lower |
| Net margin as of 2026-07-23 | +22.5% | +121.5% | RIGL higher |
| Gross margin as of 2026-07-23 | +75.0% | +93.4% | RIGL higher |
| Operating margin as of 2026-07-23 | +29.9% | +41.6% | RIGL higher |
| ROE as of 2026-07-23 | +29.9% | +147.0% | RIGL higher |
| ROA as of 2026-07-23 | +11.1% | +99.3% | RIGL higher |
| Debt / equity as of 2026-07-23 | 1.18 | 0.11 | RIGL lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.3% | +47.6% | RIGL higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +34.8% | |
| Dividend yield as of 2026-07-23 | +3.0% | n/a | |
| Beta as of 2026-07-23 | 1.17 | 1.18 | |
| 1-year return as of 2026-07-22 close | +35.8% | +88.4% | RIGL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.